Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and ECP for Sézary Syndrome and Erythrodermic Mycosis Fungoides
NCT04676087Phase 2Terminated
- Sponsor
- Emory University
- Start
- Apr 2021
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in Sézary syndrome (SS), mycosis fungoides (MF), sponsored by Emory University. Started Apr 2021; status: terminated.
02
Drugs
mogamulizumab
03
Conditions
Sézary syndrome (SS)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04676087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676087.